Roche recently stated that it had acquired Stratos Genomics, providing them with access to their unique chemistry, Sequencing by Expansion (SBX™).
Once developed, the Roche nanopore sequencer will use a novel method that mixes biological and electronic components to sequence DNA for speedy and cost-efficient clinical diagnostic testing. Also, the SBX chemistry is said to provide the healthcare community with a flexible and affordable result, for whole-genome and exome sequencing, as well as targeted clinical applications.
“Roche recently stated that it had acquired Stratos Genomics, providing them with access to their unique chemistry, Sequencing by Expansion (SBX™). “
CEO Roche Diagnostics, Thomas Scinecker, stated: “Roche is dedicated to creating innovative diagnostics for the most challenging clinical conditions with techniques that are tailored to individual genetic and disease profiles. These solutions address the demands of research and clinical practice to deliver on the promise of personalised healthcare for patients. We look forward to further advancing our sequencing technology as we move to the next generation of healthcare and welcome the world-class scientists and employees from Stratos Genomics to Roche.”
CEO and President, Stratos Genomic, Mark Kokoris, stated: “We are thrilled to join the Roche family which will allow us to combine our unique Sequencing by Expansion chemistry with the Roche nanopore sequencer. With our combined expertise and complementary technologies, we are well-positioned to open the path to deliver scalable, high-performance sequencing to clinicians and researchers.”